26 Jul 2021 18:53

Russian company Biocad starts trials of its Covid-19 vaccine - state register

MOSCOW. July 26 (Interfax) - The Russian Health Ministry has issued permission to Russian company Biocad to conduct the phase 1 and phase 2 clinical trials of its recombinant vector vaccine for Covid-19; the trials began on Monday, according to the state register of clinical trial permissions.

As many as 360 patients will take part in the vaccine's trials, which are expected to be completed by December 31, 2026.

Biocad's vaccine, BCD-250, will undergo safety and immunogenicity testing at two medical centers in St. Petersburg - the Yuninov Medical Therapy Center and the X7 Clinical Research center.

According to data from the state register, the vaccine is a solution to be administered via the intramuscular route.